Publication date: Sep 20, 2023
The bivalent (original and Omicron BA. 4/BA. 5) mRNA-1273 COVID-19 vaccine was authorized to offer broader protection against COVID-19. We conducted a matched cohort study to evaluate the effectiveness of the bivalent vaccine in preventing hospitalization for COVID-19 (primary outcome) and medically attended SARS-CoV-2 infection and hospital death (secondary outcomes). Compared to individuals who did not receive bivalent mRNA vaccination but received ≥2 doses of any monovalent mRNA vaccine, the relative vaccine effectiveness (rVE) against hospitalization for COVID-19 was 70. 3% (95% confidence interval, 64. 0%-75. 4%). rVE was consistent across subgroups and not modified by time since last monovalent dose or number of monovalent doses received. Protection was durable ≥3 months after the bivalent booster. rVE against SARS-CoV-2 infection requiring emergency department/urgent care and against COVID-19 hospital death was 55. 0% (50. 8%-58. 8%) and 82. 7% (63. 7%-91. 7%), respectively. The mRNA-1273 bivalent booster provides additional protection against hospitalization for COVID-19, medically attended SARS-CoV-2 infection, and COVID-19 hospital death.
Open Access PDF
| Concepts | Keywords |
|---|---|
| Death | Bivalent |
| Durable | Covid |
| Hospitalization | Death |
| Vaccine | Effectiveness |
| Hospital | |
| Hospitalization | |
| Infection | |
| Monovalent | |
| Mrna | |
| Omicron | |
| Original | |
| Protection | |
| Rve | |
| Sars | |
| Vaccine |
Semantics
| Type | Source | Name |
|---|---|---|
| disease | MESH | COVID-19 |
| disease | VO | vaccine effectiveness |
| disease | VO | COVID-19 vaccine |
| disease | VO | effectiveness |
| disease | VO | vaccine |
| pathway | REACTOME | SARS-CoV-2 Infection |
| disease | MESH | death |
| disease | VO | vaccination |
| disease | VO | time |
| disease | VO | dose |
| disease | MESH | emergency |
| disease | VO | effective |
| disease | MESH | morbidity |
| drug | DRUGBANK | Aspartame |
| disease | VO | USA |
| disease | MESH | infection |
| disease | VO | unvaccinated |
| disease | MESH | comorbidity |
| disease | MESH | kidney disease |
| disease | MESH | lung disease |
| disease | IDO | history |
| drug | DRUGBANK | Coenzyme M |
| disease | VO | population |
| disease | VO | vaccinated |